Get started
Author

Sarah Bruggeman

PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).
2021 · John H. Strickler, Fang-Shu Ou, et al. · Journal of Clinical Oncology · 7
Phase II trial to evaluate immune-related biomarkers for pathological response in stage II-III HER2-positive breast cancer receiving neoadjuvant chemotherapy with subsequent randomization to multi-epitope HER2 vaccine versus placebo in patients with residual disease post-neoadjuvant chemotherapy.
2022 · Saranya Chumsri, Nadine Norton, et al. · Journal of Clinical Oncology · 5
A phase I study of pharmacokinetic (PK)-driven sequential dosing of rucaparib (RUB) with irinotecan liposome (nal-IRI) and fluorouracil (5FU) in metastatic gastrointestinal (mGI) and pancreas (PANC) cancers.
2022 · Wen Wee Ma, Tyler J. Zemla, et al. · Journal of Clinical Oncology · 3
Optimized dose schedule of rucaparib and liposomal irinotecan/5‐fluorouracil in metastatic gastrointestinal cancers: A phase 1 study
2025 · Cody Eslinger, Daniel Walden, et al. · Cancer · 2
Works count: 4
Citation count: 17
H-index: 3
I10-index:
Year
Topic
Type